Great British Stock Ideas! - July 2026

🌊⚙️🔧📈

Thesis: “[It] rents specialist subsea equipment (survey tools, robotics, mechanical solutions, asset integrity systems) to the offshore energy industry… The market has looked straight past this and priced Ashtead as a pure oil price trade. At roughly 8x forward EV/EBITDA, it sits at a 2-6 turn discount to European oil services peers with lower margins and weaker competitive positions. I think that’s a mistake, and the asymmetry between downside and upside here is worth spelling out carefully.”

🚗🔍💻💰

Thesis: “Operates a subscription-based model connecting used car buyers with retailers (or dealers)… What we are looking at is a near-monopoly in the UK used car market… Generates returns on invested capital above 45%, and has maintained operating margins above 60% through most of its history as a listed company. It traded at a ten-year median P/E of almost 23x until last year, and it could be argued the market was right to assign it a premium valuation. It is not often that a company of this quality is available for less than fifty pence on the pound.”

🛡️✈️🚢🎯

Thesis: “BAE Systems is one of the clearest listed beneficiaries of the NATO defence upcycle. The company is positioned where global defence budgets are most likely to convert into funded, long-duration programmes. These include mission-essential capabilities such as nuclear submarines, naval shipbuilding, combat air, munitions, electronic warfare, space, cyber and secure mission systems.”

🏭📦📉

Thesis: “Braime is a family‑run niche industrial group trading below tangible book because it is tiny, illiquid and misunderstood. With improving earnings, vertically embedded franchises and a solid asset base, I believe that modest execution on cash generation and M&A integration could drive a meaningful re‑rating.”

🏦📊🔄

Thesis: “UK-focused wealth management group providing discretionary investment management, financial planning, and managed portfolio services… The BRK investment case is centred on whether the ‘Reignite Growth’ strategy — with net flow recovery as its primary metric — will create value and take BM from a structurally challenged mid-tier operator into growth mode again.”

🧬🎗️⚠️

Thesis: “[It] has assembled what could be one of the more compelling small-cap oncology investment cases in London… For investors who understand the asset class, have sized the position appropriately for the binary risk profile, and can hold through the inevitable volatility of a small-cap AIM biotech, Coiled is one of the more interesting risk-reward propositions in London’s oncology investment landscape right now.”

🍺🏨💷

Thesis: “Daniel Thwaites is a hospitality business with the three divisions… Nothing spectacular but it is certainly worth more than its current market cap. Today’s company is selling at 36% of its liquidation value; that’s a huge margin of safety… I feel confident that there is a low probability of permanent capital loss coupled with a high chance of above average returns at these prices for Daniel Thwaites shares.”

⚛️💡🚀

Thesis: “Tech start-up with a simple but potentially powerful business model: fund cutting-edge quantum computing research at world-class universities, own the resulting intellectual property, and license it to the companies… Delta Gold’s current market cap, even after substantial share price appreciation, remains tiny relative to that opportunity. That asymmetry is the core of the investment case.”

🔌🏭📈

Thesis: “Global designer and manufacturer of highly engineered, customised electronic components supplying industrial end markets… Valuation has come down significantly during two years of negative organic revenue growth. We believe the causes of the downturn are temporary in nature. At c.11x forward earnings, the valuation is attractive for a quality business with proven management, growth potential both organic and from M&A, potential for margin improvement, strong cash generation and a conservative balance sheet.”

Share British Alpha

📄🏭✨

Thesis: Papermaking and advanced materials company. “Takeover rumours persistently swirl around James Cropper, partly because of its expertise and partly because, well it is just so damn undervalued by the market… a genuine manufacturing turnaround into a high performance materials company with two structural moats, a clean balance sheet, confirmed FCF inflection, and a management team that is executing well. Why is the market is still pricing it like a Victorian paper mill? This is where the opportunity lies. The Wizard puts James Cropper as a strong buy with a target price of c. £10.”

🍦🍫📈

Thesis: Ice cream company. “A high ceiling of opportunity as MICC is currently trading at the wrong multiple on deeply depressed earnings. The long is timely as MICC will lap a generational cocoa spike that will roll off hedges over the next several quarters among other non-recurring spinoff expenses in H2’26. On management’s organic growth algorithm, I see ~80% upside. In my more ambitious organic case and re-rate to a “fair” comp set, I see over ~130% gains in shares today. “

🧪💧🔬⚖️

Thesis: “The established gold standard for rapid toxicity testing… A textbook asymmetric microcap bet. It has a proprietary moat (Lightning-fast Microtox IP + 70% margin reagent lock-in), massive macro tailwinds (PFAS, desalination, water security), and a proven razor/razor-blade model reaching operational scale. However, we must respect that it is navigating something of a narrow strait… The strategic vision and capabilities being built look spot on. All for only £2m or so. Dare we say… A drop in what looks like a very large ocean of opportunity. The upside/downside asymmetry is roughly 8:1.”

💾🧠📈

Thesis: Semiconductor manufacturer. The market has re-rated Micron’s revenue but not its identity — it still trades at a cheap 10–12x forward P/E, as if its record earnings are a temporary cyclical peak rather than a structural shift. The core argument is that AI has made memory bandwidth the key bottleneck in computing, and Micron sits at the centre of that trend, making it significantly undervalued.

🪨🌍💰

Thesis: Rare earth elements junior miner. “Sum-of-the-parts value of approximately 7.3 times the current share price, before any risk adjustment. Even after applying conservative execution discounts, the base case valuation still gives us a 5x upside. Three world-class businesses, each one arguably worth more than the entire company by itself, packaged into a single London- and Toronto-listed entity trading at 51p… So a comfortable 5-6x at base case… The market sees a cash-burning junior. The numbers show a cash-printing machine waiting to be switched on.”

🥤🌍💷

Thesis: “A UK-based branded beverage company that has sold its Vimto brand fruit-flavoured soft drinks since 1908…. This is a simple thesis. Nichols is a clean, steady business that is growing organically (~6.5% EBIT CAGR) driven by a booming African segment, produces a lot of FCF with minimal capital reinvestment (~1 million capex annually), and trades at TTM 12.3x EV/Op EPS. I think that is too cheap for a business of this quality and that shareholders will do well from the current price.”

🥤🏆📉

Thesis: “118-year-old maker of Vimto and other soft drinks…With the kind of characteristics that have historically supported reliable dividend growth over long periods. The past is no guarantee of the future, of course. Nichols lack of family management could see the company lose its focus, while its niche brand – albeit a large niche – could eventually reach growth limits as fashions and tastes change… Despite these concerns, I think the valuation, balance sheet and trading outlook all point to a potential opportunity – if the company can avoid further missteps.”

💎⛏️🏴

Thesis: “Owns two of South Africa’s most storied underground diamond mines… You are paying £57m for two world-class mines with multi-decade lives. I accept the balance sheet is ugly, the dilution is real, and the Rand is an ever-present risk. But the prevailing perception is that the market is anchored to the going-concern narrative, which no longer applies, while underpricing the operational turnaround underway.”

🛢️🇪🇺💰⚡

Thesis: Energy investment company. Trading at roughly 3p — an implied 60% discount to its risked NAV of 13.6p per share — backed by cash-generating producing assets in Italy and Spain, a new management team focused on capital discipline, and a structurally supportive macro backdrop post-Russia’s invasion of Ukraine. The thesis holds that the market is mispricing both the floor value of existing production and the optionality across multiple near-term development catalysts, and its new Polish licences, making it a compelling value setup for patient investors over the next 18 months.

🧾🏦🌏📈

Thesis: IFRS life insurer. “Buy PRU at the liquidation value of its existing insurance book and get a franchise writing $2.8bn of annual new business value, at 22%+ IRRs across 19 Asian and African markets, for free. Collect ~5% annual return from dividends plus buybacks while you wait for a valuation re-rating that should follow the completion of a three-year operational transformation in 2027.”

🛢️🌍💵

Thesis: A fully integrated global energy company with strong process power - spanning upstream drilling, refining, LNG, and retail - giving it a high barrier to entry that few competitors can match. At a P/E of around 13, it trades at a significant discount to peers Exxon and Chevron, whilst leading the group on share buybacks and dividend growth, making it the analyst’s preferred holding in the sector.

⚙️🏭📈

Thesis: “A world-leading industrial engineering group.” “Spirax is a mispriced, high-quality industrial compounder poised for a significant re-rating as it emerges from cyclical headwinds, with the market underappreciating the recovery in its crown-jewel (Watson-Marlow segment) and the margin expansion potential from in the Electric Thermal segment.”

🏠🔨📊

Thesis: Housebuilder. “It remains… exposed to mortgage rates, buyer confidence and housing-market sentiment. But the investment case looks materially stronger than it did eighteen months ago. The bank debt has gone. The landbank has been partially validated above book value. The shares still trade at a meaningful discount to tangible net assets. And the North Scotland opportunity gives the company an additional growth angle that is perhaps not available to most UK housebuilders… The valuation provides the margin of safety. The North Scotland opportunity provides the upside.”

🌊🛡️⚡

Thesis: “The market leader in Cable Protection Systems… This is by far the most attractive opportunity I see on just about any market at the moment, not only because of the upside, but also because the downside looks well defended here. I think it would be very difficult to lose money investing in Tekmar as things stand. At anything below 22p per share, this is a truly magical buy.”

🏨🏢⚖️

Thesis: “a FTSE 100 hospitality company and the owner and operator of Premier Inn.” “The stock currently trades at just over £24, close to its five-year low and the stock price has gone backwards over the last five years… This dislocation attracted Corvex Management, a proven activist, which took a 6% stake in December 2025 and has publicly forced management to reassess their Five-Year Plan, including the £3.5bn investment programme. The downside is anchored by the property floor. The upside is a forced capital allocation reset, with a hard public deadline of April 30th.”

🌍💸🔗

Thesis: Wise disrupts the expensive traditional banking system by using a direct, ledger-based infrastructure to facilitate faster, low-cost international transfers. The company leverages a scalable flywheel model—combining personal and business accounts with its Wise Platform infrastructure—to capture a massive global payment market while maintaining strong management alignment with shareholders.